Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin

Roman Zazula, Miroslav Prucha, Tomas Tyll, Eva Kieslichova, Roman Zazula, Miroslav Prucha, Tomas Tyll, Eva Kieslichova

Abstract

Introduction: The aim of this study was to compare the early postoperative kinetics of procalcitonin (PCT) and C-reactive protein (CRP) serum levels in patients undergoing orthotopic liver transplantation (OLTx) with different immunosuppressive regimens.

Methods: PCT and CRP serum concentrations were measured in a group of 28 OLTx recipients before induction of anesthesia, at 4 and 8 hours following graft reperfusion, and daily until postoperative day 4. The same parameters were determined in 12 patients undergoing liver resection without conjunctive immunosuppressive therapy. Summary data are expressed as medians and ranges. Two-tailed nonparametric tests were performed and considered significant at p values of less than 0.05.

Results: The highest serum levels of PCT (median 3.0 ng/mL, minimum 1.4 ng/mL, maximum 13.9 ng/mL) were found in patients after OLTx without ATG therapy, on postoperative day 1. In patients with ATG administration, PCT levels were highly increased on postoperative day 1 (median 53.0 ng/mL, minimum 7.9 ng/mL, maximum 249.1 ng/mL). Thereafter, PCT values continuously decreased independently of further ATG administration in both groups of patients. No evidence of infection was present in either group. In 12 patients undergoing liver resection, peak serum PCT levels did not exceed 3.6 ng/mL. CRP serum levels in a group of patients with and without ATG therapy increased significantly on postoperative day 1, followed by a decrease. The highest levels of CRP were found in patients after liver resection on postoperative day 2 and decreased thereafter.

Conclusion: ATG administration to patients with OLTx is associated with an increase in serum PCT levels, with peak values on postoperative day 1, and this was in the absence of any evidence of infection. The results of this study indicate that ATG immunosuppressive therapy is a stimulus for the synthesis of PCT.

Figures

Figure 1
Figure 1
Procalcitonin (PCT) serum levels in patients after orthotopic liver transplantation (OLTx) with and without anti-thymocyte globulin (ATG) therapy and after liver resection.
Figure 2
Figure 2
C-reactive protein (CRP) serum levels in patients after orthotopic liver transplantation (OLTx) with and without anti-thymocyte globulin (ATG) therapy and after liver resection. n.s., not significant.

References

    1. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin. 2006;22:503–519. doi: 10.1016/j.ccc.2006.03.003.
    1. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996–2003. doi: 10.1097/01.CCM.0000226413.54364.36.
    1. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34:2596–2602. doi: 10.1097/01.CCM.0000239116.01855.61.
    1. Eberhard OK, Langefeld I, Kuse ER. Procalcitonin in the early phase after renal transplantation-will it add to diagnostic accuracy. Clin Transplant. 1998;12:206–211.
    1. Kunz D, Pross M, König W, Lippert H, Manger T. Diagnostic relevance of procalcitonin, IL-6 and cellular immune status in the early phase after liver transplantation. Transplant Proc. 1998;30:2398–2399. doi: 10.1016/S0041-1345(98)00667-8.
    1. Kuse ER, Langefeld I, Jaeger K, Kulpmann WR. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 2000;28:555–559. doi: 10.1097/00003246-200002000-00044.
    1. Stríz I, Jaresová M, Lácha J, Sedlácek J, Vítko S. MRP 8/14 and procalcitonin serum levels in organ transplantations. Ann Transplant. 2001;6:6–9.
    1. Kuse ER, Jaeger K. Procalcitonin increase after anti-CD3 monoclonal antibody therapy does not indicate infectious disease. Transpl Int. 2001;14:55. doi: 10.1111/j.1432-2277.2001.tb00011.x.
    1. Sabat R, Höflich C, Döcke WD, Oppert M, Kern F, Windrich B, Rosenberger C, Kaden J, Volk HD, Reinke P. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med. 2001;27:987–991. doi: 10.1007/s001340100949.
    1. Nylen ES, Whang KT, Snider RH, Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26:1001–1006. doi: 10.1097/00003246-199806000-00015.
    1. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32:1715–1721. doi: 10.1097/01.CCM.0000134404.63292.71.
    1. Silomon M, Bach F, Ecker D, Graeter T, Grundmann U, Larsen R. Procalcitonin after extracorporeal circulation. Synthesis in the hepatosplanchnic region. Anaesthesist. 1999;48:395–398. doi: 10.1007/s001010050718.
    1. Meisner M, Müller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19:187–190. doi: 10.1097/00024382-200302000-00017.
    1. Redl H, Schiesser A, Tögel E, Assicot M, Bohuon C. Possible role of TNF on procalcitonin release in a baboon model of sepsis. Shock. 2001;16:25–27.
    1. Fazakas J, Gondos T, Varga M, Sarvary E, Horovitz P, Perner F. Analysis of systemic and regional procalcitonin serum levels during liver transplantation. Transpl Int. 2003;16:465–470. doi: 10.1111/j.1432-2277.2003.tb00334.x.
    1. Redl H, Schlag G, Tögel E, Assicot M, Bohuon C. Procalcitonine release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. Crit Care Med. 2000;28:3659–3663. doi: 10.1097/00003246-200011000-00021.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever